70 citations
,
September 2017 in “Expert opinion on therapeutic patents” This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.
45 citations
,
January 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.
8 citations
,
June 2023 in “European Journal of Endocrinology” This study identified serum androsterone as a robust biomarker for monitoring response to AKR1C3 inhibitor treatment in women and found that a 4-week administration of aldo-keto reductase 1C3 inhibitors did not impact ovarian function.
6 citations
,
February 2023 in “Journal of nanobiotechnology” In this study, HA-P5, a nanoparticle derived from peptide and polysaccharide conjugation, effectively reduced acne lesions and sebum production by inhibiting specific receptors in cells, without triggering unfavorable reactions compared to a commercial inhibitor, highlighting HA-P5's potential as a novel acne treatment.
December 1998 in “福井大学教育学部紀要 第4部 教育科学” This study found that the bioconjugate nanoparticle HA-P5 significantly alleviated acne and reduced sebum production by inhibiting key signaling pathways without inducing unwanted protein expression that hinders acne treatment.